protagonist-inc

BioSpace covers ICOTYDE™ FDA Approval

Sat, 28 Mar 2026 16:49:35 GMT

March 18, 2026

Please note: the "View Article" button directs you to an external website.

U.S. FDA Approves ICOTYDE™ (icotrokinra)

Sat, 28 Mar 2026 15:54:55 GMT

March 18, 2026

Barclays Global Healthcare Conference

Thu, 12 Mar 2026 23:26:27 GMT

Date: March 12, 2026

Please note: the "View Webcast" button directs you to an external website.

Barclays 28th Annual Global Healthcare Conference

Wed, 25 Feb 2026 00:23:31 GMT

Format: Fireside Chat
Day/Time: Thursday, March 12 at 11:30 A.M. ET

Please note: the "View Webcast" button directs you to an external website.

Citizens Life Sciences Conference

Wed, 25 Feb 2026 00:21:54 GMT

Format: Fireside Chat
Day/Time: Wednesday, March 11 at 1:05 P.M. ET

Please note: the "View Webcast" button directs you to an external website.

Jefferies Biotech on the Beach Summit

Tue, 24 Feb 2026 19:45:31 GMT

Format: One-on-one Meetings
Day/Time: Tuesday, March 10

Location: Miami, FL

Leerink Global Healthcare Conference

Tue, 24 Feb 2026 19:42:26 GMT

Format: Fireside Chat
Day/Time: Monday, March 9 at 4:20 P.M. ET

Please note: the "View Webcast" button directs you to an external website.

TD Cowen 46th Annual Health Care Conference; Boston, MA

Tue, 24 Feb 2026 19:38:12 GMT

Format: Fireside Chat
Day/Time: Tuesday, March 3 at 11:50 A.M. ET

Please note: the "View Webcast" button directs you to an external website.

Protagonist CEO Dinesh V. Patel and Chief Discovery Officer Ashok Bhandari Speak with BiotechTV

Thu, 19 Feb 2026 02:58:18 GMT

February 19, 2026

Please note: the "Learn More" button directs you to an external website.

Protagonist Speaks to BioSpace at #JPM26

Fri, 16 Jan 2026 18:57:33 GMT

January 16, 2026

Please note: the "Learn More" button directs you to an external website.

Protagonist at the J.P. Morgan Healthcare Conference

Tue, 13 Jan 2026 19:50:58 GMT

January 13, 2026

Corporate Presentation

Mon, 12 Jan 2026 19:24:07 GMT

January 12, 2026

Protagonist at the Evercore Healthcare Conference

Wed, 03 Dec 2025 14:25:22 GMT

December 4, 2025

Please note: the "View Webcast" button directs you to an external website.

Protagonist at the Citi Global Healthcare Conference

Mon, 01 Dec 2025 22:05:35 GMT

December 2, 2025

Please note: the "View Webcast" button directs you to an external website.

TD Cowen Advancements in Obesity Summit

Wed, 26 Nov 2025 21:11:56 GMT

November 24, 2025

Protagonist CEO Dinesh V. Patel on our programs and culture of partnering at #Jefferies25

Fri, 21 Nov 2025 16:52:58 GMT

November 18, 2025 | by BiotechTV

Please note: the "Watch Video" button directs you to an external website.

Protagonist at the Jefferies Global Healthcare Conference

Wed, 19 Nov 2025 20:09:05 GMT

November 19, 2025

Please note: the "View Webcast" button directs you to an external website.

Protagonist at the TD Cowen Immunology & Inflammation Summit

Sun, 16 Nov 2025 21:57:12 GMT

November 12, 2025

Please note: the "View Webcast" button directs you to an external website.

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

Mon, 06 Oct 2025 14:09:49 GMT

Kremyanskaya M, et al. N Engl J Med. 2024;390(8):723-35

2025 European Academy of Dermatology and Venerology Congress

Wed, 17 Sep 2025 13:29:51 GMT

PN-881: First-in-class oral peptide targeting the IL-17 pathway

Manrique M, et al

Protagonist at the H.C. Wainwright Global Investment Conference

Tue, 09 Sep 2025 18:52:36 GMT

September 9, 2025

Please note: the "View Webcast" button directs you to an external website.

Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Wed, 03 Sep 2025 19:31:02 GMT

Results from VERIFY, An International, Randomized Phase 3 Double-blind Placebo-controlled Study of Rusfertide (First-In-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV)

Pemmaraju N, et al

Protagonist at the Citigroup 2025 Biopharma Conference

Wed, 03 Sep 2025 14:56:43 GMT

September 3, 2025

Please note: the "View Webcast" button directs you to an external website.

MPN Workshop of the Carolinas 2025

Fri, 22 Aug 2025 19:32:26 GMT

VERIFY, A Phase 3 Placebo-Controlled Study Investigating Rusfertide With Current Standard of Care Therapy in Patients With Polycythemia Vera

Pemmaraju N, et al

Protagonist Announces Nomination of PN-477, an Oral and Injectable Peptide Development Candidate for Obesity

Mon, 30 Jun 2025 17:57:57 GMT

June 30, 2025

Please note: the "View Webcast" button directs you to an external website.

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Fri, 27 Jun 2025 21:35:00 GMT

Monday, June 30th at 4:30 pm ET

US-based Investors: 1-877-407-0752

International Investors: 1-201-389-0912

Conference Call ID: 13754335

Protagonist at the Jefferies Global Healthcare Conference

Thu, 05 Jun 2025 15:54:11 GMT

June 4, 2025

CEO Dinesh V. Patel speaks at the Jefferies Global Healthcare Conference.

Post-ASCO Update: Phase 3 VERIFY Study Results

Mon, 02 Jun 2025 12:37:17 GMT

Please note: the "View Webcast" button directs you to an external website.

CEO Dinesh V. Patel Speaks With BiotechTV at #ASCO25

Sun, 01 Jun 2025 01:20:27 GMT

June 1, 2025

Watch CEO Dinesh V. Patel’s interview, courtesy of BiotechTV.

Please note: the "Watch Interview" button directs you to an external website.

American Society of Clinical Oncology 2025 Annual Meeting

Fri, 30 May 2025 19:35:17 GMT

Adaptation of ASCO’25 Phase 3 VERIFY Plenary Presentation

Kuykendall AT, et al

Protagonist at the Jefferies Global Healthcare Conference

Wed, 21 May 2025 13:59:29 GMT

June 3-5, 2025

Format: Company Presentation
Day/Time: Wednesday, June 4 at 1:25 P.M. ET

2025 Society For Investigative Dermatology

Wed, 07 May 2025 13:31:43 GMT

PN-881: First-in-class oral peptide targeting the IL-17 pathway

Manrique M, et al

Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Thu, 01 May 2025 21:01:20 GMT

Presenting Author: Andrew T. Kuykendall, M.D. (Moffitt Cancer Center)

Title: Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV)

Abstract: LBA3

Session Name: Plenary Session
Session Date: Sunday, June 1, 2025
Presentation Time: 2:09 PM - 2:21 PM CDT
Location: McCormick Place, Hall B1

Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling.

Fri, 11 Apr 2025 13:40:28 GMT

Knight B, et al. Dermatol Ther (Heidelb). 2025;15(9):2495-520

Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.

Fri, 04 Apr 2025 13:59:04 GMT

Modi NB, et al. Clin Pharmacol Drug Dev. 2025;14(4):311-23

Protagonist Therapeutics Is One of Fast Company’s Most Innovative Companies of 2025

Tue, 18 Mar 2025 12:27:18 GMT

March 18, 2025

Please note: the "View Article" button directs you to an external website.

Protagonist Investor Conference Call and Webcast

Mon, 03 Mar 2025 13:57:07 GMT

March 3, 2025 at 8:30 am ET

US-based Investors: 1-877-300-8521

International Investors: 1-412-317-6026

Conference Call ID: 1793905

FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Mon, 03 Mar 2025 13:45:35 GMT

Ferris LK, et al. J Am Acad Dermatol. 2025 Mar;92(3):495-502

Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.

Tue, 11 Feb 2025 13:43:19 GMT

Stein Gold L, et al. Adv Ther. 2025;42(7):3158-172

Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide

Thu, 06 Feb 2025 18:10:10 GMT

February 6, 2025

Protagonist at the J.P. Morgan 43rd Annual Healthcare Conference

Tue, 14 Jan 2025 17:00:54 GMT

#JPM25

Tuesday, January 14, 2025

ASH REVIVE Final Analysis Poster

Tue, 10 Dec 2024 22:22:36 GMT

December 10, 2024

66th American Society of Hematology (ASH) Annual Meeting and Exposition

Sat, 07 Dec 2024 19:36:40 GMT

Final Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Gerds A, et al

Endpoints News: J&J and Protagonist Announce Phase 3 Trial Results for icotrokinra (JNJ-2113, formerly PN-235)

Mon, 25 Nov 2024 19:58:46 GMT

November 19, 2024

Please note: the "View Article" button directs you to an external website.

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Thu, 21 Nov 2024 01:38:30 GMT

November 21, 2024

Conference Call and Webcast Details

The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:

US-based Investors : 1-877-407-0752

International Investors : 1-201-389-0912

Conference Call ID : 13750274

Webcast Link >

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor

Mon, 18 Nov 2024 21:58:04 GMT

November 18, 2024

Please note: the "View Press Release" button directs you to an external website.

Protagonist at the The 66th Annual American Society of Hematology (ASH) Annual Meeting

Wed, 06 Nov 2024 21:45:40 GMT

December 7-10, 2024

Presenting author: Aaron Gerds, MD (Cleveland Clinic)

Publication Number: 4559

Title: Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 9, 2024
Presentation Time: 6:00 PM - 8:00 PM PST
Location: San Diego Convention Center, Halls G-H

16th International Congress on Myeloproliferative Neoplasms (MPN Congress)

Thu, 24 Oct 2024 19:38:34 GMT

Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients: Hematocrit Control and Therapeutic Phlebotomy Frequency

Gerds A, et al

Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers

Thu, 03 Oct 2024 14:01:55 GMT

Modi NB, et al. Drugs R D. 2024;24(4):539-52

Protagonist at the H.C. Wainwright 26th Annual Global Investment Conference

Tue, 10 Sep 2024 14:53:24 GMT

September 9 - 11, 2024

2024 American College of Clinical Pharmacology (ACCP) Annual Meeting

Sun, 08 Sep 2024 19:47:55 GMT

Pharmacokinetics, Pharmacodynamics and Safety of Rusfertide, a Hepcidin Mimetic, in Subjects with Hepatic Impairment and in Subjects with Renal Impairment

Modi N, et al

Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians

Wed, 14 Aug 2024 10:06:28 GMT

Kuykendall AT, et al. Clin Lymphoma Myeloma Leuk. 2024;24(8):512-22

Nature: JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Thu, 01 Aug 2024 17:29:52 GMT

July 30, 2024

Please note: the "View Article" button directs you to an external website.

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Tue, 30 Jul 2024 13:49:12 GMT

Fourie AM, et al. Sci Rep. 2024;14(1):17515

EHA 2024 Oral Presentation: Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients

Wed, 26 Jun 2024 19:48:31 GMT

June 26, 2024

2024 European Hematology Association (EHA) Meeting

Thu, 13 Jun 2024 19:49:17 GMT

Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients: Hematocrit Control and Therapeutic Phlebotomy Frequency

Pettit KM, et al

Protagonist at the Jefferies Global Healthcare Conference

Thu, 06 Jun 2024 12:13:22 GMT

June 4-6, 2024

Protagonist at the Jefferies Global Healthcare Conference

Thu, 06 Jun 2024 12:00:17 GMT

June 5, 2024 at 11:00 AM (ET)

American Society of Clinical Oncology 2024 Annual Meeting

Fri, 31 May 2024 19:50:38 GMT

VERIFY: A Randomized Controlled Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PV)

Bankar A, et al

Protagonist at the The Citizens JMP Life Sciences Conference

Wed, 15 May 2024 12:49:37 GMT

May 13, 2024

Protagonist at the The Citizens JMP Life Sciences Conference

Mon, 13 May 2024 12:21:31 GMT

May 13, 2024

10th Translational Research Conference: Myeloproliferative Neoplasms

Fri, 26 Apr 2024 19:51:30 GMT

Biomarker Profiling of Patients with Polycythemia Vera Relative to Healthy Subjects: Baseline Characteristics of Patients Enrolled in the PACIFIC Study

Modi N, et al

Protagonist at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Fri, 29 Mar 2024 20:34:48 GMT

March 28, 2024

Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study

Wed, 13 Mar 2024 14:03:51 GMT

Modi NB, et al. Eur J Haematol. 2024;113(3):340-50

An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Wed, 07 Feb 2024 13:51:58 GMT

Bissonnette R, et al. N Engl J Med. 2024;390(6):510-21

Please note: the "View Publication" button directs you to an external website.

6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference

Mon, 29 Jan 2024 20:44:42 GMT

February 7-8, 2024

Presentation: Thursday, February 8 at 9:00-9:25 A.M. EST

Location: St. Regis New York, Two E. 55th Street, New York, NY 10022

On Demand Recording

Protagonist at the 42nd Annual J.P. Morgan Healthcare Conference

Wed, 10 Jan 2024 13:10:48 GMT

January 8-11, 2024

Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial

Thu, 14 Dec 2023 14:16:16 GMT

Kowdley KV, et al. Lancet Gastroenterol Hepatol. 2023;8(12):1118-28

Please note: the "View Publication" button directs you to an external website.

ASH 2023 Oral Presentation: Durability of Hematocrit Control in Polycythemia Vera With the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results From the REVIVE Study

Tue, 12 Dec 2023 13:15:45 GMT

December 11, 2023

ASH 2023 Oral Presentation: Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

Tue, 12 Dec 2023 13:13:28 GMT

December 11, 2023

ASH 2023 Poster Presentation: Rusfertide Improves Markers Of Iron Deficiency In Patients With Polycythemia Vera

Tue, 12 Dec 2023 13:11:59 GMT

December 11, 2023

ASH 2023 Poster Presentation: Prevalence Of Second Cancers In Patients With Polycythemia Vera (PV): A Retrospective Analysis Of Us Real-World Claims Data

Tue, 12 Dec 2023 13:09:56 GMT

December 11, 2023

ASH 2023 Poster Presentation: Iron Restricted Erythropoiesis Under Hepcidin Mimetic Treatment (PN23114) Improves Disease Parameters In A Mouse Model For Sickle Cell Disease

Tue, 12 Dec 2023 13:07:53 GMT

December 11, 2023

Protagonist Therapeutics CEO Dinesh V. Patel on our hepcidin memetic and oral IL-23 program at #ASH23

Mon, 11 Dec 2023 16:06:18 GMT

By BiotechTV | December 11, 2023

Protagonist CEO Dinesh V. Patel discusses our experience in peptide engineering, an update on the rusfertide program in polycythemia vera and the exciting future of JNJ-2113 on the sidelines of #ASH23.

65th American Society of Hematology (ASH) Annual Meeting and Exposition

Sat, 09 Dec 2023 19:53:30 GMT

Durability of Hematocrit Control in Polycythemia Vera With the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results From the REVIVE Study

Ritchie, EK, et al

Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

Kuykendall AT, et al

Rusfertide Improves Markers of Iron Deficiency in Patients With Polycythemia Vera

Ginzburg Y, et al

Prevalence Of Second Cancers In Patients With Polycythemia Vera (PV): A Retrospective Analysis Of US Real-World Claims Data

Pemmaraju N, et al

65th American Society of Hematology (ASH) Annual Meeting and Exposition

Sat, 09 Dec 2023 13:10:51 GMT

Iron Restricted Erythropoiesis under Hepcidin Mimetic Treatment (PN23114) Improves Disease Parameters in a Mouse Model for Sickle Cell Disease

Taranath R, et al

J&J notebook: Highlights from a day of pipeline and strategy discussion

Wed, 06 Dec 2023 22:25:16 GMT

By Max Gelman | December 6, 2023

Johnson & Johnson laid out their pipeline and medtech strategies Tuesday, promising 20 new drugs that can help grow sales 5% to 7% a year through 2030, starting with $57 billion in 2025. R&D chief John Reed, in an earlier interview with Endpoints News, said their three pillars of focus would be oncology, immunology and neuroscience.

Protagonist at the Jefferies London Healthcare Conference

Thu, 16 Nov 2023 13:09:02 GMT

November 14-16, 2023

Summary of Malignancies Observed Across 5 Phase 2 Open Label Clinical Trials of the Hepcidin Mimetic Rusfertide

Thu, 02 Nov 2023 21:15:00 GMT

Pemmaraju N, et al

15th International Congress on Myeloproliferative Neoplasms (MPN Congress)

Thu, 02 Nov 2023 19:56:16 GMT

Summary of Malignancies Observed Across 5 Phase 2 Open Label Clinical Trials of the Hepcidin Mimetic Rusfertide

Oral IL 23 Receptor Peptide Antagonist JNJ 2113: The Journey from De Novo Discovery to Phase 3 Clinical Development Program

Mon, 23 Oct 2023 18:22:35 GMT

JNJ 77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients With Plaque Psoriasis

Mon, 16 Oct 2023 17:32:15 GMT

Results From the Phase 2, FRONTIER 1 Study

A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study of Oral JNJ 77242113 for the Treatment of Moderate to Severe Plaque Psoriasis

Mon, 16 Oct 2023 17:30:50 GMT

Efficacy of Overall and Scalp Psoriasis Responses From FRONTIER 1

Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide: Blinded Randomizated Withdrawal Results of the Phase 2 Revive Study

Mon, 11 Sep 2023 12:05:44 GMT

Pemmaraju N, et al

Society of Hematologic Oncology (SOHO) 2023 Annual Meeting

Wed, 06 Sep 2023 19:57:11 GMT

Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide: Blinded Randomizated Withdrawal Results of the Phase 2 REVIVE Study

Amgen tipped to keep Otezla market share in fight with BMS' Sotyktu, leaving opportunity for J&J

Tue, 05 Sep 2023 13:01:45 GMT

By Nick Paul Taylor | September 5, 2023

Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics.

Protagonist at the H.C. Wainwright 25th Annual Global Investment Conference

Tue, 05 Sep 2023 12:54:21 GMT

September 11-13, 2023

Fireside chat with Doug Tsao, Managing Director, Senior Healthcare Analyst

Date: Tuesday, September 12, 2023

Time: 12:30 p.m. ET

Location: Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY 10022

Wells Fargo 2023 Healthcare Conference

Tue, 05 Sep 2023 12:47:50 GMT

September 5-7, 2023

Fireside chat with Derek Archila, Managing Director, Biotechnology Equity

Research Date: Thursday, September 7, 2023

Time: 8:45 a.m. ET

Location: Encore Boston Harbor, 1 Broadway, Everett, Massachusetts

Formulas for Success from Biotechs that Leaped in Value Despite the Downturn

Thu, 31 Aug 2023 13:07:04 GMT

By Lauren Martz, BioCentury | August 31, 2023

Rusfertide in PV (REVIVE) - Late Breaking Oral Presentation June 11, 2023

Tue, 13 Jun 2023 12:37:38 GMT

Pharmacokinetic and Pharmacodynamic Effects of Rusfertide In Polycythemia Vera: Results from an Ongoing Phase 2 Study in Patients with Elevated Hematocrit Values

Mon, 12 Jun 2023 12:30:50 GMT

Rusfertide (PTG-300) Improves Polycythemia Vera (PV) Related Symptoms in PV Patients

Sun, 11 Jun 2023 12:26:23 GMT

2023 European Hematology Association (EHA) Meeting

Thu, 08 Jun 2023 19:57:57 GMT

Targeted Therapy Of Uncontrolled Erythrocytosis In Polycythemia Vera With The Hepcidin Mimetic, Rusfertide: Blinded Randomized Withdrawal Results Of The REVIVE Study

Kremyanskaya et al

2023 World Congress of Dermatology

Mon, 29 May 2023 19:58:47 GMT

July 3-8, 2023

Singapore

Title: A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER 1

Speaker: Bissonnette R (Canada)

Date and Time: July 4, 2023, 14:50 - 15:00

https://www.wcd2023singapore.org/

2023 Annual Congress of the European Hematology Association

Sun, 14 May 2023 18:52:20 GMT

June 8-11, 2023

Frankfurt, Germany

Title: Rusfertide (PTG-300) improves polycythemia vera (PV) related symptoms in PV patients

Abstract Code: P1016

Presenting Author: Andrew Kuykendall , M.D., Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center

Session Date and Time: Friday, June 9, 18:00 - 19:00 CEST

Title: Pharmacokinetic and pharmacodynamic effects of rusfertide in polycythemia vera: Results from an ongoing Phase 2 study in patients with elevated hematocrit values

Abstract Code: P1048
Presenting Author: Marina Kremyanskaya , M.D., Ph.D., Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Session Date and Time: Friday, June 9 , 18:00 - 19:00 CEST

Full abstract information can be found on the EHA 2023 Hybrid Congress website at https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/.

First-In-Class Oral Peptide Systemically Targeting The IL-23 Pathway

Fri, 12 May 2023 15:11:40 GMT

Protagonist at the Jefferies Healthcare Conference

Fri, 12 May 2023 12:12:25 GMT

July 7-9, 2023

Marriott Marquis, 1535 Broadway, New York, NY 10036

Presentation: Protagonist Therapeutics, Inc.

Date and Time: 6/7/2023 9:00 AM (ET)

CEO Dinesh Patel Talks Culture, Collaboration and Courage

Tue, 28 Feb 2023 14:10:51 GMT

5 Questions With Dinesh Patel, PhD, CEO Protagonist Therapeutics

1. PROTAGONIST HAS A CLEAR GOAL OF SERVING PATIENTS MOST IN NEED. TELL US ABOUT HOW YOU ARE ACHIEVING YOUR MISSION.

At Protagonist we strive to improve patient lives by targeting areas of unmet need in both rare diseases and prevalent diseases where current treatments are limited or inadequate.

We currently have seven new projects in the discovery and preclinical pipeline. We also have three assets in various clinical studies; one to help combat blood disorders, and the other two in inflammatory and immunomodulatory diseases (with one of them in partnership with Janssen).

Rusfertide (PTG-300) is a novel injectable synthetic mimetic of the natural hormone hepcidin with superior properties in comparison to the natural hormone. Based on the excellent efficacy data obtained in a phase 2 study, we are moving rusfertide in a phase 3 study to treat polycythemia vera, a form of blood cancer that causes bone marrow to make too many red blood cells.

PN-235 is an oral peptide and is often referred to as the ‘oral Stelara’ or a ‘Tremfya in a pill’ since it blocks the same biological pathway that is targeted by these injectable antibody drugs. PN-235 is partnered with Janssen and is currently in multiple studies for treatment of psoriasis.

PN-943 is a first-in-class oral, alpha-4- beta-7 (α4β7) integrin-specific antagonist peptide. After completing a phase 2 study, we are currently seeking regulatory guidance for the next study with this drug candidate as a potential possible treatment for ulcerative colitis (UC).

2. THE DEVELOPMENT OF PEPTIDE DRUGS HAS BECOME ONE OF THE HOTTEST AREAS IN PHARMACEUTICAL RESEARCH. HOW IS YOUR APPROACH UNIQUE?

For us, it has been a 14-plus year journey leading to a proprietary technology platform, a highly specialized team of technical experts, and numerous ‘secret sauce’ recipes in the field of peptide therapeutics. This enables us to discover peptides in a de novo fashion against a wide variety of targets and diseases, and engineer the desired degree of potency, specificity and selectivity, solubility, metabolic stability, and manufacturability with specific peptidomimetic and chemical modifications.

The ultimate proof of success comes in the form of three peptide-based drug candidates I mentioned — rusfertide, PN-235 partnered with Janssen, and PN-943 — that were all discovered internally and are currently in advanced stages of clinical development. With oral peptides PN-235 and PN-943, we have also broken the barrier towards ‘oral peptides,’ which is often considered the holy grail in the field of peptides.

3. MANY COMPANIES PRIORITIZE DISCOVERY OR DEVELOPMENT. WHAT ARE YOU MOST PASSIONATE ABOUT?

It is a balancing act between discovery and development, and we need both to succeed at the ultimate goal of getting more effective medicine in the hands of patients who need it the most. While we have a staple of matured clinical development assets, in many ways we remain a discovery company at heart. I am proud to lead our company toward advancing our peptide technology platform for the de novo discovery of first-and best-inclass drugs.

Our combination of diverse scientific and operational talent has enabled our success. Our discovery is strong, and the ability to implement and achieve a successful outcome with an asset that germinates from discovery and progresses into clinical development — and hopefully ultimately gets approved in the future — comes from the strength of our team members.

I strive to inspire my team by demonstrating that achieving transformational innovation means committing to a challenging and long journey. I believe that creating a culture of passion, conviction and transparency that honors and leverages the unique and special talents of an individual or team is what leads to ultimate success.

4. YOU’VE EXPERIENCED MARKET DOWNTURNS IN THE BIOTECH INDUSTRY. WHAT IS YOUR SECRET TO SUCCESS?

Having been in the business of biopharma and biotech for more than thirty years, I know that market highs and downturns like the one we are in currently are inevitable. As a leader, it is so important to stay focused and confident during the tough times. That is where transformation happens—especially when you’ve built a dynamic, diversified business with multiple revenue streams, partnerships, and assets.

Innovating new medicines that address unmet patient needs is tremendously rewarding, and more often than not, hugely challenging. A secret to our longevity has been humbleness, always staying grounded, and the unbridled optimism that the best is always yet to come.

5. WHAT IS YOUR VISION FOR PROTAGONIST, AND HOW ARE YOU NAVIGATING THE COMPANY TOWARDS A SUCCESSFUL FUTURE?

My singular focus is on innovating and developing new drugs, and finding the most expedited and effective ways of getting them to the patients who need them the most. We have multiple shots on goal with three assets in advanced clinical development. With rusfertide, we are on the threshold of achieving a radically improved therapy for a blood cancer like polycythemia vera. We have an astute, strategic team of innovators and builders who will continue to focus on creating differentiated, unique, and transformational healthcare solutions that were once considered impossible.

Protagonist: Inclusion by the Numbers

Fri, 24 Feb 2023 17:38:51 GMT

Spotlight: Carena Spivey, Head of HR

Carena, equality, inclusion, and workplace diversity have long been in focus at Protagonist, as expressed through various programs and initiatives. Can you tell us about your approach?

We view our diverse and welcoming corporate culture as being critical to our long-term success – It’s essential to the way we innovate. And we regularly track and report our progress, because we believe that what doesn’t get measured doesn’t get done.

Today:

- 65% of employees are members of underrepresented ethnic communities

- 51% are women - nearly 50% of our Board identifies as a member of an underserved community or as female

What are you doing to help create a more diverse employee community?

We create the conditions for our employees to thrive, facilitating their learning and growth through a richly supportive workplace setting.

Part of that is creating a speak-up culture; we have cultivated an environment where every voice is heard, and we encourage the expression of different points of view in decision-making processes. At every turn, we encourage deep listening, thoughtful consideration, and open-mindedness that allows for decisions to be changed or refined in step with new data. By embracing our team members’ differences, we create wins for our organization and for patients.

Improving Access to Medicines, Ensuring Diverse Representation

Thu, 23 Feb 2023 17:43:11 GMT

Spotlight: Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.

Join Our Polycythemia Vera VERIFY Clinical Study

Wed, 22 Feb 2023 17:23:19 GMT

Consider joining the VERIFY study to learn more about an investigational study drug called rusfertide for polycythemia vera.

If you have received at least 3 phlebotomies in the last 6 months or at least 5 within in the last year for inadequate hematocrit control, you may qualify.

Polycythemia Vera: Mechanism of Disease

Tue, 21 Feb 2023 16:10:32 GMT

WATCH VIDEO

Cancer Moonshot: How We’re Helping Patients

Tue, 14 Feb 2023 16:23:03 GMT

NEWS

Blood Cancer Awareness - What You Need to Know Now

Tue, 31 Jan 2023 17:32:07 GMT

How many people are affected by blood cancers?

1.5 million individuals in the United States are either living with, or in remission from, blood cancers. ¹

What are types of blood cancer?

Leukemia, lymphoma, and myeloma are considered the primary types of blood cancers which impact the body’s blood cells. ²

Other rare types of blood cancers, such as polycythemia vera – a disease for which Protagonist is working to address - can sometimes progress into cancers like leukemia.

Where does blood cancer originate from?

Bone cancers start in the bone marrow, the source of blood production; patients with blood cancer will typically have too many white blood cells in their bone marrow, as the old white blood cells are not replaced with new ones. ³

By contrast, in patients with polycythemia vera, too many red blood cells are produced; the high red blood cell count will generally lead to slowed blood flow and poor oxygenation. ⁴ This poses a significant risk of blood clots, stroke, heart attacks, and organ and tissue damage. ⁵

What is the cause of blood cancers?

According to the Cleveland Clinic, although research indicates that blood cancers are caused by DNA mutations, there is evidence to suggest that various genetic and environmental factors may play a role in blood cancer. ⁶

What are reported signs and symptoms of patients with blood cancer?

Patients with blood cancer often report signs and symptoms that include fever and chills, unexplained weight loss, weakness, ongoing fatigue, swollen lymph nodes, bruising, excessive night sweats, and bone pain. ⁷ Polycythemia vera patients tend to report signs and symptoms like itchiness, numbness, tingling, bleeding, joint swelling, and trouble with breathing when lying down. ⁸

How are patients diagnosed?

When diagnosing a patient, the patient’s doctor will typically collect a medical history, complete a physical examination, and request blood work and various imaging tests. ⁹ They typically measure hematocrit – the proportion of red blood cells in your blood. Many physicians now believe an appropriate hematocrit level is below 45.

What treatment options exist?

Several treatment options exist for blood cancers, and many more are being researched. In the treatment of polycythemia vera, Protagonist Therapeutics is developing rusfertide, an investigational drug currently in Phase 3 clinical studies. The current standard of care is phlebotomy, a blood draw procedure that has a number of challenges for patients.

¹ https://www.lls.org/blood-cancer-awareness#:~:text=September%20is%20Blood%20Cancer%20Awareness,in%20remission%20from%20blood%20cancers.

² https://bloodcancer.org.uk/understanding-blood-cancer/#:~:text=Blood%20cancer%20is%20a%20type,the%20DNA%20within%20blood%20cells.

³ https://www.yalemedicine.org/conditions/blood-cancers

⁴

⁵ USAToday ad

⁶ https://my.clevelandclinic.org/health/diseases/22883-blood-cancer#symptoms-and-causes

⁷ https://www.mayoclinic.org/diseases-conditions/leukemia/symptoms-causes/syc-20374373

⁸ https://www.mayoclinic.org/diseases-conditions/polycythemia-vera/symptoms-causes/syc-20355850#:~:text=Polycythemia%20vera%20(pol%2De%2D,Polycythemia%20vera%20is%20rare.

⁹ https://my.clevelandclinic.org/health/diseases/22883-blood-cancer#symptoms-and-causes

Real‑World Treatments and Thrombotic Events in Polycythemia Vera Patients in the USA

Fri, 13 Jan 2023 15:19:46 GMT

J.P. Morgan 2023 Healthcare Conference Company Presentation

Wed, 11 Jan 2023 15:14:03 GMT

January 11, 2023

41st Annual J.P. Morgan Health Care Conference

Thu, 29 Dec 2022 13:49:36 GMT

January 9 -12, 2023

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in REVIVE: A Phase 2 Study in Patients with Polycythemia Vera

Fri, 23 Dec 2022 19:18:59 GMT

Presentation Type: at Conference

Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment

Thu, 22 Dec 2022 19:21:37 GMT

PTG-300 (Rusfertide) Treatment Interruption Reverses Hematological Gains And Restores Therapeutic Benefit On Reinitiation In Subjects With Polycythemia Vera

Wed, 21 Dec 2022 19:24:53 GMT

Presentation Type: at Conference

The Hepcidin Mimetic Rusfertide as a Treatment for Hereditary Hemochromatosis

Tue, 20 Dec 2022 19:27:34 GMT

ASH 2022 Poster Presentation: Rusfertide analog-PN23114 as a hepcidin mimetic provides efficacy benefits in conjunction with phlebotomy in mouse model for hereditary hemochromatosis

Sun, 11 Dec 2022 22:11:43 GMT

December 11, 2022

ASH 2022 Poster Presentation: Subgroup analysis of Adverse Events following rusfertide dosing in REVIVE: A Phase 2 study in patients with polycythemia vera

Sun, 11 Dec 2022 12:30:50 GMT

December 11, 2022

64th American Society of Hematology (ASH) Annual Meeting and Exposition

Sat, 10 Dec 2022 13:15:29 GMT

Rusfertide Analog-PN23114 as a Hepcidin Mimetic Provides Efficacy Benefits in Conjunction with Phlebotomy in Mouse Model for Hereditary Hemochromatosis (Oral Presentation)

Taranath R, et al

Rusfertide Analog-PN23114 as a Hepcidin Mimetic Provides Efficacy Benefits in Conjunction with Phlebotomy in Mouse Model for Hereditary Hemochromatosis (Poster)

Taranath R, et al

ASH 2022 Poster Presentation: VERIFY: A Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera

Sat, 10 Dec 2022 13:06:17 GMT

December 10, 2022

ASH Annual Meeting & Exposition

Sat, 10 Dec 2022 12:47:14 GMT

December 10, 2022

64th American Society of Hematology (ASH) Annual Meeting and Exposition

Sat, 10 Dec 2022 12:12:00 GMT

Analysis Of Adverse Events Following Rusfertide Dosing In REVIVE: A Phase 2 Study In Patients With Polycythemia Vera (Oral Presentation)

Pemmaraju N, et al

Subgroup Analysis Of Adverse Events Following Rusfertide Dosing In REVIVE: A Phase 2 Study In Patients With Polycythemia Vera (Poster)

Pemmaraju N, et al

VERIFY: A Phase 3 Study Of The Hepcidin Mimetic Rusfertide (PTG-300) In Patients With Polycythemia Vera (Oral Presentation)

Verstovsek S, et al

VERIFY: A Phase 3 Study Of The Hepcidin Mimetic Rusfertide (PTG-300) In Patients With Polycythemia Vera (Poster)

Verstovsek S, et al

SOHO Rusfertide Presentation

Thu, 29 Sep 2022 12:11:20 GMT

September 29, 2022

Society of Hematologic Oncology (SOHO) 2022 Annual Meeting

Wed, 28 Sep 2022 12:12:50 GMT

Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit is Observed in Patients With Polycythemia Vera

Pemmaraju N, et al

California Life Sciences Cancer Moonshot

Mon, 29 Aug 2022 12:24:52 GMT

August 29, 2022

EHA 2022 Poster Presentation

Thu, 09 Jun 2022 12:28:40 GMT

June 9, 2022

2022 European Hematology Association (EHA) Meeting

Thu, 09 Jun 2022 12:13:34 GMT

PTG-300 (Rusfertide) Treatment Interruption Reverses Hematological Gains And Restores Therapeutic Benefit On Reinitiation In Subjects With Polycythemia Vera

Kuykendall A, et al

Protagonist at the Jefferies Healthcare Conference

Wed, 08 Jun 2022 12:33:29 GMT

June 8, 2022 09:30 AM ET

ASCO 2022 Presentation

Tue, 07 Jun 2022 13:58:54 GMT

June 07, 2022

American Society of Clinical Oncology 2022 Annual Meeting

Fri, 03 Jun 2022 12:14:19 GMT

Rusfertide (PTG-300) Treatment in Phlebotomy-Dependent Polycythemia Vera

Hoffman R, et al

Annual Meeting of Stockholders

Thu, 26 May 2022 14:01:32 GMT

May 26, 2022 01:00 PM ET

A list of stockholders entitled to vote at the Annual Shareholder Meeting will be available for examination for any purpose germane to the Annual Shareholder Meeting for ten days prior to the Annual Shareholder Meeting. You may email ir@ptgx-inc.com to coordinate arrangements to view the stockholder list.

IDEAL PN-943 DDW 2022 Presentation

Wed, 25 May 2022 14:58:20 GMT

May 25, 2022

A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted ɑ4β7 integrin peptide antagonist PN-943

Tue, 24 May 2022 19:13:22 GMT

A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted ɑ4β7 integrin peptide antagonist PN-943 in patients with moderate to severe ulcerative colitis: the IDEAL Study

PN-943 Phase 2 Data Readout – Conference Call

Mon, 25 Apr 2022 19:45:52 GMT

April 25, 2022 06:00 PM ET

11th Annual SVB Leerink Global Healthcare Conference

Thu, 17 Feb 2022 20:48:16 GMT

February 17, 2022 03:00 PM ET

40th Annual J.P. Morgan Healthcare Conference

Tue, 11 Jan 2022 20:52:55 GMT

January 11, 2022 02:15 PM ET

Protagonist at the H.C. Wainwright BioConnect 2022 Conference

Mon, 10 Jan 2022 20:54:16 GMT

January 10, 2022 07:00 AM ET

PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis

Thu, 16 Dec 2021 14:30:19 GMT

Sandborn WJ, et al. Gastroenterology 2021;161:1853-64

ASH 2021 Presentation

Sun, 12 Dec 2021 22:10:20 GMT

December 12, 2021

63rd American Society of Hematology (ASH) Annual Meeting and Exposition

Sat, 11 Dec 2021 13:17:40 GMT

Regulation of Iron Homeostasis and Efficacy of Rusfertide Analog Peptide in a Mouse Model for Polycythemia Vera

Taranath R, et al

63rd American Society of Hematology (ASH) Annual Meeting and Exposition

Sat, 11 Dec 2021 12:15:15 GMT

Rusfertide (PTG-300) Controls Hematocrit Levels and Essentially Eliminates Phlebotomy Requirement in Polycythemia Vera Patients

Hoffman R, et al

Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hematocrit Control in Polycythemia Vera Patients without the Need for Therapeutic Phlebotomy

Ginzburg Y, et al

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Verstovsek S, et al

Rusfertide (PTG-300), A Hepcidin Mimetic, Maintains Liver Iron Concentration in the Absence of Phlebotomies in Patients with Hereditary Hemachromatosis

Knowdley K, et al

JMP Securities Hematology and Oncology Summit - 1:40 PM ET

Mon, 06 Dec 2021 22:08:31 GMT

December 6, 2021 01:40 PM ET

Regulation of Iron Homeostasis by PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia & Hereditary Hemochromatosis

Wed, 01 Dec 2021 19:36:49 GMT

Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models

Wed, 01 Dec 2021 19:29:40 GMT

Hepcidin Peptidomimetics - Oral Efficacy in Pre-Clinical Disease Models for Iron Overload and Erythrocytosis

Wed, 01 Dec 2021 19:29:05 GMT

Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers

Tue, 30 Nov 2021 20:17:09 GMT

Piper Sandler 33rd Annual Healthcare Conference

Mon, 22 Nov 2021 22:07:13 GMT

November 22, 2021 10:00 AM ET

Protagonist at the Jefferies London Healthcare Conference

Thu, 18 Nov 2021 22:05:56 GMT

November 18, 2021 03:00 AM ET

The Liver Meeting®: AASLD 2021 Oral Presentation

Sat, 13 Nov 2021 22:04:41 GMT

November 13, 2021 10:00 AM PT

Protagonist at the Jefferies Next Generation IBD Therapeutics Virtual Summit

Tue, 19 Oct 2021 23:00:04 GMT

October 19, 2021 10:45 AM ET

Protagonist at the Jefferies Next Generation IBD Therapeutics Summit

Tue, 19 Oct 2021 21:03:15 GMT

October 19, 2021 10:45 AM ET

Protagonist Regulatory Update Conference Call

Mon, 11 Oct 2021 21:01:58 GMT

October 11, 2021 08:00 AM ET

Investor Call on Updated Janssen Agreement

Wed, 28 Jul 2021 21:00:51 GMT

July 28, 2021 05:00 PM ET

European Hematology Association ("EHA") 2021 Annual Congress

Fri, 11 Jun 2021 20:59:59 GMT

June 11, 2021 09:00 AM ET

Title: Rusfertide (PTG-300) Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera (PV) Patients
Session: Novel therapies and targets in MPN
Abstract Number: S200
Presenter: Marina Kremyanskaya, MD, PhD, Assistant Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai

EHA2021 Corporate Event: Conference Call and Webcast

Fri, 11 Jun 2021 20:53:26 GMT

June 11, 2021 08:00 AM ET

Management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera (PV), which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress. The conference call will take place on Friday, June 11, 2021, at 8:00 a.m. EDT (14:00 CEST).

The call will feature members of the Protagonist management team and Ronald Hoffman, M.D., Albert A. and Vera G. List Professor of Medicine, Hematology and Medical Oncology, and Director of the Myeloproliferative Disorders Research Program at Mount Sinai Hospital, and a lead investigator of the Phase 2 study.

To access the live call, dial (877) 870-4263 (U.S./Canada) or (412) 317-0790 (international) five minutes prior to the call and ask to be joined to the Protagonist Therapeutics call. A live and archived webcast will be accessible in the Investors section of the Company’s website at www.protagonist-inc.com .

Protagonist at the Jefferies Virtual Healthcare Conference

Tue, 01 Jun 2021 20:52:15 GMT

June 1-4, 2021

Annual Meeting of Stockholders

Thu, 27 May 2021 20:50:48 GMT

May 27, 2021 10:00 AM PT

Protagonist Corporate Update Call

Mon, 22 Mar 2021 20:47:08 GMT

March 22, 2021 05:00 PM ET

Protagonist Therapeutics Fourth Quarter and Year-end Financial Results

Wed, 10 Mar 2021 21:42:32 GMT

March 10, 2021 04:30 PM ET

Protagonist at the H.C. Wainwright Global Life Sciences Conference

Tue, 09 Mar 2021 21:41:01 GMT

March 9, 2021 07:00 AM ET

Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers

Mon, 08 Mar 2021 14:23:48 GMT

Modi NB et al. Clin Pharmacol Drug Dev. 2021;10(11):1263-78

10th Annual SVB Leerink Global Healthcare Conference

Wed, 24 Feb 2021 21:39:29 GMT

February 24, 2021 10:40 AM ET

39th Annual J.P. Morgan Healthcare Conference

Mon, 11 Jan 2021 21:37:17 GMT

January 11, 2021 02:00 PM ET

PN-943, an Oral α4β7 Integrin Antagonist, Inhibits MAdCAM1-Mediated Proliferation and Cytokine Release from CD4+ T-Cells Independent of Trafficking

Sun, 20 Dec 2020 20:19:04 GMT

Research and Development (R&D) and Corporate Update

Thu, 10 Dec 2020 00:13:26 GMT

December 9, 2020 08:30 AM ET

Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis

Mon, 07 Dec 2020 19:43:25 GMT

Roopa Taranath, Gregory Bourne, Jie Zhang, Brian Frederick, Tran T Tran, Ashok Bhandari, Jayanthi Vengalam, Jaimee McMahon, Keith Huie, Grace A Ledet, Li Zhao, James Tovera, Larry Lee, Bo Yang, Celino Dion, Lucy Yuan, Genet Zemede, Michelle Nguyen, Mohammad Masjedizadeh, Xiaoli Cheng, Larry Mattheakis, David Liu, Mark L Smythe, The 62nd ASH Annual Meeting and Exposition, December 5-8, 2020, virtual meeting (originally scheduled for San Diego, California, USA).

PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients

Sun, 06 Dec 2020 19:44:31 GMT

Marina Kremyanskaya, Yelena Ginzburg, Andrew Kuykendall, Abdulraheem Yacoub, Jay Yang, Suneel Gupta, Frank Valone, Sarita Khanna, Srdan Verstovsek, and Ronald Hoffman, The 62nd ASH Annual Meeting and Exposition, December 5-8, 2020, virtual meeting (originally scheduled for San Diego, California, USA).

PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients

Sun, 06 Dec 2020 19:42:13 GMT

Kremyanskaya M, Ginzburg Y, Kuykendall AT, et al., The 62nd ASH Annual Meeting and Exposition, December 5-8, 2020, virtual meeting (originally scheduled for San Diego, California, USA).

62nd ASH Annual Meeting and Exposition

Sun, 06 Dec 2020 00:11:42 GMT

December 5-8, 2020

32nd Annual Piper Sandler Healthcare Conference

Mon, 30 Nov 2020 20:57:59 GMT

November 30 - December 3, 2020

Protagonist at the Jefferies London Healthcare Conference

Wed, 18 Nov 2020 00:03:53 GMT

November 17, 2020 12:35 PM ET

Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models

Thu, 05 Nov 2020 19:46:18 GMT

Roopa Taranath, Larry Mattheakis, Li Zhao, Larry Lee, James Tovera, Jingsong Zhao, Xiaoli Cheng, David Liu, The 62nd ASH Annual Meeting and Exposition, December 5-8, 2020, virtual meeting (originally scheduled for San Diego, California, USA).

Protagonist at the H.C. Wainwright 22nd Annual Global Investment Conference

Mon, 14 Sep 2020 23:01:23 GMT

September 14, 2020 11:00 AM ET

Protagonist Therapeutics PTG-300 Opportunity Update Webinar

Fri, 11 Sep 2020 22:58:36 GMT

September 11, 2020 12:00 PM ET

BMO Prescriptions for Success Healthcare Conference

Tue, 23 Jun 2020 22:56:53 GMT

June 23, 2020 01:00 PM ET

Raymond James Human Health Innovations Conference

Thu, 18 Jun 2020 19:37:01 GMT

June 18, 2020 01:40 PM ET

Protagonist at the Jefferies Virtual Healthcare Conference

Wed, 03 Jun 2020 22:54:53 GMT

June 3, 2020 10:30 AM ET

Annual Meeting of Stockholders

Thu, 28 May 2020 22:53:51 GMT

May 28, 2 020 10:00 PM PT

A list of stockholders entitled to vote at the Annual Shareholder Meeting will be available for examination for any purpose germane to the Annual Shareholder Meeting for ten days prior to the Annual Shareholder Meeting. You may email protagonist@troutgroup.com to coordinate arrangements to view the stockholder list.

Protagonist Corporate and R&D Update Call

Thu, 07 May 2020 22:48:47 GMT

May 7, 2020 05:00 PM ET

Protagonist Therapeutics 2019 Year-End Update Call

Tue, 10 Mar 2020 22:45:34 GMT

March 10, 2020 04:30 PM ET

SVB Leerink Global Healthcare Conference

Tue, 25 Feb 2020 23:44:31 GMT

February 25, 2020 10:30 AM ET

The Oral α4β7 Integrin Specific Antagonist PN-10943 is More Effective than PTG-100 in Multiple Preclinical Studies

Fri, 20 Dec 2019 20:20:54 GMT

Piper Healthcare Conference

Thu, 05 Dec 2019 14:24:08 GMT

December 5, 2019 01:30 PM ET

PTG-300 beta-thalassemia update

Tue, 03 Dec 2019 14:23:22 GMT

December 3, 2019 08:30 AM ET

Stifel 2019 Healthcare Conference

Wed, 20 Nov 2019 14:21:56 GMT

November 20, 2019 02:25 PM ET

Regulation of Iron Homeostasis By PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia and Hereditary Hemochromatosis

Wed, 13 Nov 2019 19:47:47 GMT

Roopa Taranath, Gregory Bourne, Li Zhao, Brian Frederick, Chelsea King, David Liu, The 61st ASH Annual Meeting and Exposition, December 7-19, 2019, Orlando, Florida, USA.

(ACG 2019) Safety, Tolerability, and Pharmacokinetics of PTG-200, An Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, In Normal Healthy Volunteers

Wed, 30 Oct 2019 19:38:36 GMT

(UEGW 2019) Safety, Tolerability, And Pharmacokinetics Of PTG-200, An Oral Gi-Restricted Peptide Antagonist Of IL-23 Receptor, In Normal Healthy Volunteers

Wed, 23 Oct 2019 19:41:39 GMT

Cantor Global Healthcare Conference

Wed, 02 Oct 2019 13:20:52 GMT

October 2, 2019 02:25 PM ET

Protagonist at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference

Tue, 10 Sep 2019 13:19:44 GMT

September 10, 2019 09:10 AM ET

BMO 2019 Prescription for Success Healthcare Conference

Tue, 25 Jun 2019 13:18:49 GMT

June 25, 2019 03:40 PM ET

Annual Meeting of Stockholders

Fri, 07 Jun 2019 13:16:40 GMT

June 7, 2019 10:00 AM PT

101 California Street, Fifth Floor, San Francisco, CA 94010

Digestive Disease Week (DDW)

Sat, 18 May 2019 12:58:12 GMT

May 18-21, 2019

The Oral α4β7 Integrin Specific Antagonist PN-10943 is More Effective Than PTG 100 in Multiple Preclinical Studies
Presenting Author: Larry Mattheakis, PhD, Sr. VP, Discovery Biology and Translational Research

Protagonist Corporate Update Call

Wed, 08 May 2019 12:56:25 GMT

May 8, 2019 08:30 AM ET

Protagonist at the H.C. Wainwright & Co. Global Life Sciences Conference

Tue, 09 Apr 2019 12:51:56 GMT

April 9, 2019 9:50 AM BST

Q4 2018 Protagonist Therapeutics Inc Earnings Conference Call

Tue, 12 Mar 2019 12:45:26 GMT

March 12, 2019 04:30 PM ET

Leerink Partners 8th Annual Global Healthcare Conference

Thu, 28 Feb 2019 12:53:50 GMT

February 28, 2019 09:00 AM ET

BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

Wed, 12 Dec 2018 18:01:52 GMT

December 12, 2018 09:20 AM ET

Protagonist Corporate Update Call

Tue, 27 Nov 2018 16:10:53 GMT

November 27, 2018 04:30 PM ET

PTG-100, an Oral Gut-Restricted Peptide α4β7 Antagonist, Induces Clinical and Histologic Remission in Patients with Moderate to Severely Active Ulcerative Colitis

Thu, 22 Nov 2018 20:22:51 GMT

United European Gastroenterology Week Meeting

Sat, 20 Oct 2018 15:05:00 GMT

October 20-24, 2018 12:00 PM ET

Location: ACV, Vienna, Austria

Presentation Title: PTG-100, an oral gut-restricted peptide alpha-4-beta-7 antagonist induces clinical and histologic remission in patients with moderate to severely active ulcerative colitis
Session: Room C – Clinical trials in IBD

Cantor Fitzgerald Global Healthcare Conference

Mon, 24 Sep 2018 14:59:48 GMT

September 24, 2018 07:00 AM ET

InterContinental New York Barclay Hotel

PROPEL Study and PTG-100 Program Update Conference Call

Mon, 06 Aug 2018 14:58:51 GMT

August 6, 2018 08:00 AM ET

2018 JMP Securities Life Sciences Conference

Wed, 20 Jun 2018 14:58:07 GMT

June 20, 2018 02:00 PM ET

Hepcidin mimetic PTG-300 for treatment of ineffective erythropoiesis and chronic anemia in hemoglobinopathy diseases

Mon, 18 Jun 2018 14:57:13 GMT

June 18, 2018

Hepcidin Mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects

Sat, 16 Jun 2018 14:54:50 GMT

June 16, 2018

23rd Congress of the European Hematology Association (EHA)

Thu, 14 Jun 2018 14:16:28 GMT

June 14-17, 2018 12:00 PM ET

Stockholm, Sweden Stockholm International Fairs 125 30 Stockholm Sweden

Presentation Title: Hepcidin mimetic PTG-300 for treatment of ineffective erythropoiesis and chronic anemia in hemoglobinopathy diseases
Date and Time: Saturday, June 16 from 11:45 AM to 12:00 PM CEST
Session: Thalassemias
Location: Stockholm International Fairs Convention Center, Room K2

Presentation Title: Hepcidin Mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects
Date and Time: Saturday, June 16 from 5:00 PM to 5:15 PM CEST
Session: Iron metabolism, deficiency and overload
Location: Stockholm International Fairs Convention Center, Room A13

Digestive Diseases Week® (DDW) Conference

Sat, 02 Jun 2018 14:13:40 GMT

June 2, 2018 12:00 PM ET

Location: Walter E. Washington Convention Center in Washington, D.C. United States

Presentation Title: Oral delivery of peptides with dual mu/delta opioid receptor agonist activities are superior to eluxadoline in preclinical models of IBS-D
Session: Diarrhea and Irritable Bowel Syndrome - New Advances
Presenting author: Larry Mattheakis, Vice President of Biology, Protagonist Therapeutics, Inc.

Annual Meeting of Stockholders

Tue, 29 May 2018 13:48:36 GMT

May 29, 2018 11:00 AM PT

Conference Center Pacific Research Center 7677 Gateway Blvd. Newark, California 94560

Hepcidin Mimetic PTG-300 Induces Dose-Related and Sustained Reductions in Serum Iron and Transferrin Saturation in Healthy Subjects

Thu, 17 May 2018 18:49:30 GMT

Andrew Nicholls, Jason Lickliter, Lucio Tozzi, David Liu, Richard Shames, 23rd Eurpopean Haematology Congress, June 14-17, 2018, Stockholm, Sweden.

Oral peptides with dual mu/delta opioid receptor agonist activities are superior to eluxadoline in preclinical models of IBS-D

Tue, 01 May 2018 19:51:29 GMT

Protagonist Therapeutics Inc Conference Call

Mon, 26 Mar 2018 13:43:39 GMT

March 26, 2018 08:00 AM ET

Protagonist Therapeutics Inc at 28th Annual Oppenheimer Healthcare Conference

Wed, 21 Mar 2018 13:42:13 GMT

March 21, 2018 03:20 PM ET

The Westin New York Grand Central hotel in New York, NY United States

Protagonist Therapeutics Inc at Barclay's Global Healthcare Conference

Thu, 15 Mar 2018 13:41:08 GMT

March 15, 2018 11:15 AM ET

Protagonist Therapeutics, Inc. 2017 Year-End Update Call

Wed, 07 Mar 2018 14:40:10 GMT

March 7, 2018 04:30 PM ET

BTIG’s 2018 Healthcare Conference

Mon, 26 Feb 2018 14:39:01 GMT

February 26 - March 2, 2018

Snowbird, UT United States

Leerink Partners 7th Annual Global Healthcare Conference

Wed, 14 Feb 2018 14:38:07 GMT

February 14, 2018 09:30 AM ET

Lotte New York Palace in New York, NY United States

The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in Preclinical Model of IBD

Wed, 20 Dec 2017 20:43:26 GMT

Model Based Predictions of the PTG-100 Pharmacodynamic Responses in Ulcerative Colitis Patients

Wed, 20 Dec 2017 20:24:56 GMT

BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Thu, 14 Dec 2017 18:28:12 GMT

December 14, 2017 08:00 AM ET

Westin Grand Central Hotel, New York, NY United States

Protagonist Therapeutics Inc at Stifel 2017 Healthcare Conference

Wed, 15 Nov 2017 18:26:51 GMT

November 15, 2017 10:15 AM ET

Lotte New York Palace Hotel in New York, NY United States

Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Iron Overload Diseases

Sat, 14 Oct 2017 18:54:01 GMT

Greg Bourne, Li Zhao, Ashok Bhandari, Brian Frederick, Jaimee McMahon, Jenny Zhang, Adam Stephenson, Thamil Annamalai, Larry Mattheakis, Dinesh Patel, Mark Smythe, David Liu, 6th Modern Solid Phase Peptide Synthesis & Its Applications Symposium 2017, October 12-14, 2017, Fraser Island, Australia.

2017 Cantor Fitzgerald Global Healthcare Conference

Tue, 26 Sep 2017 17:25:08 GMT

September 26, 2017 08:35 AM ET

InterContinental New York Barclay Hotel New York, NY United States

Orally Delivered Peptides for Treatment of Inflammatory Bowel Disease

Tue, 13 Jun 2017 19:54:26 GMT

Protagonist Business Update

Tue, 30 May 2017 17:23:58 GMT

May 30, 2017 08:00 AM ET

Teleconference details: toll-free 844-515-9178 or toll call +1-614-999-9313, conference ID number 30341699

Annual Meeting of Stockholders

Thu, 25 May 2017 17:22:06 GMT

May 25, 2017 10:00 AM PT

Conference Center Pacific Research Center 7677 Gateway Blvd. Newark, CA 94560

Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Chronic Anemia in Hemoglobinopathy Diseases

Wed, 17 May 2017 18:50:49 GMT

Greg Bourne, Li Zhao, Ashok Bhandari, Brian Frederick, Vinh Tran, Jenny Zhang, Adam Stephenson, Roopa Taranath, James Tovera, Thamil Annamalai, Larry Mattheakis, Mark Smythe, David Liu, 23rd Eurpopean Haematology Congress, June 14-17, 2018, Stockholm, Sweden.

Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Iron Overload

Thu, 11 May 2017 19:09:57 GMT

Gregory Bourne, Li Zhao, Ashok Bhandari, Brian Frederick, Jaimee McMahon, Vinh Tran, Jenny Zhang, Adam Stephenson, James Tovera, Lu Bai, Thamil Annamalai, Dinesh Patel, Mark Smythe, and David Liu, Seventh Congress of the International BioIron Society (IBIS), May 7-11, 2017, Los Angeles, California, USA.

Digestive Diseases Week

Sat, 06 May 2017 17:19:22 GMT

May 6-9, 2017 12:00 PM ET

Chicago, Illinois United States

Presentation Title: The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in a Preclinical Model of IBD
Date and Time: Saturday, May 6 from 11:15 AM to 11:30 AM CT
Location: McCormick Place, Room S102d

Oxford Global’s 4th Annual Peptide Congress

Mon, 24 Apr 2017 17:17:12 GMT

April 24-25, 2017 12:00 PM ET

London, UK, Novotel London West United States

Session: Advances in Peptide Therapeutics
Presentation: Discovery & Development of PTG-100, an Oral Peptide Antagonist of α4β7 Integrin, in Clinical Development for the Treatment of Inflammatory Bowel Disease
Presenter: Ashok Bandari, Ph.D., Vice President, Chemistry, Protagonist Therapeutics
Date and Time: 9-9:30 AM BST, Tuesday April 25
Room: Conference Room 3- Epernay

Drug Discovery Chemistry

Sun, 23 Apr 2017 17:15:34 GMT

April 23-27, 2017 12:00 PM ET

San Diego, CA, Sheraton San Diego Hotel and Marina United States

Presentation: Biomarker Discovery and Development of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor
Meeting: 8th Annual Inflammation Inhibitors: Small Molecule Approaches for Oral-based Therapeutics
Presenter: Larry Mattheakis, Ph.D., Vice President, Biology, Protagonist Therapeutics

Date and Time: 10:35 am PT, Monday April 24

Presentation: Discovery & Development of PTG-100, an Oral Peptide Antagonist of α4β7 Integrin, for the Treatment of Inflammatory Bowel Disease
Meeting: 5th Annual Macrocyclics and Constrained Peptides: Bigger, Better and Still Oral Small Molecules
Presenter: Ashok Bandari, Ph.D., Vice President, Chemistry, Protagonist Therapeutics

Date and Time: 2:20 PM PT, Wednesday April 26

Oppenheimer & Co. Healthcare Conference

Tue, 21 Mar 2017 17:11:24 GMT

March 21, 2017 02:10 PM ET

Westin New York Grand Central hotel, New York, NY. United States

Barclays Global Healthcare Conference 2017

Tue, 14 Mar 2017 17:10:09 GMT

March 14, 2017 02:05 PM ET

Miami, FL, Loews Miami Beach Hotel United States

Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer

Leerink Partners 6th Annual Global Healthcare Conference

Thu, 16 Feb 2017 18:08:42 GMT

February 16, 2017 11:00 AM ET

New York, NY, Lotte New York Palace United States

Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer

12th Congress of ECCO (European Crohn's and Colitis Organization)

Wed, 15 Feb 2017 18:06:09 GMT

February 15-18, 2017 12:00 PM ET

Location: Barcelona, Spain United States

Poster Number:P113

Poster Title: Model based predictions of the PTG-100 pharmacodynamic responses in Ulcerative Colitis patients

Date and Time: February 17, 2017 12:30-13:30

Presenting Author:Larry Mattheakis

Poster Number:P001

Poster Title:The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in a Preclinical Model of IBD

Date and Time:February 17, 2017 12:30-13:30

BMO Capital Markets, Prescriptions for Success Healthcare Conference

Wed, 14 Dec 2016 18:35:16 GMT

December 14, 2016 02:20 PM ET

New York, NY United States

2016 Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation of America’s Clinical & Research Conference

Thu, 08 Dec 2016 18:33:39 GMT

December 8-9, 2016 12:00 PM ET

Orlando, FL United States

Poster Number:P-271

Poster Title:The Biomarker Profile of PTG-200, An Oral Peptide Antagonist of IL-23 Receptor, Correlates with Efficacy in Preclinical Models of IBD

Date and Time:Friday, December 9, 2016 06:00 PM - 07:00 PM ET

Poster Location:Exhibit Hall - Atlantic B-C

Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23

Wed, 23 Nov 2016 20:55:46 GMT

BioEurope 2016

Mon, 07 Nov 2016 18:31:41 GMT

November 7-9, 2016 12:00 PM ET

Cologne Germany United States

Pharmacokinetics and Pharmacodynamics Following Oral Administration Of PTG-100, a Peptide Antagonist of Integrin α4β7

Wed, 19 Oct 2016 19:27:06 GMT

Safety, Pharmacokinetics and Pharmacodynamics of the Novel Oral Peptide Therapeutic PTG-100 (α4β7 Integrin Antagonist) in Normal Healthy Volunteers

Tue, 18 Oct 2016 19:29:22 GMT

UEG Week

Sat, 15 Oct 2016 17:12:12 GMT

October 15-19, 2016 12:00 PM ET

Vienna Austria United States

Poster Number: P0298

Poster Title: Safety, Pharmacokinetics and Pharmacodynamics of the Novel Oral Peptide Therapeutic PTG-100 (alpha4-beta7 Integrin Antagonist) in Normal Healthy Volunteers

Date and Time: Monday October 17, 10:30 - 17:00, presentation 12:30 - 13:30 CET

Presenting Author: Richard S. Shames, MD, Protagonist Chief Medical Officer

Poster Number: P0792

Poster Title: Pharmacokinetics and Pharmacodynamics Following Oral Administration of PTG-100, a Peptide Antagonist of Integrin alpha4-beta7

Date and Time: Tuesday October 18, 9:00 to 17:00, presentation 12:30 - 13:30 CET

Presenting Author: Thamil Annamalai, M.S., Protagonist Senior Director, Preclinical Development

Establishing the Human Equivalent Dose for PTG-100, an Oral Peptide Antagonist of Integrin α4β7

Sat, 01 Oct 2016 19:31:21 GMT

Protagonist Therapeutics Inc at 252nd American Chemical Society National Meeting & Exposition

Tue, 23 Aug 2016 17:29:52 GMT

August 23, 2016 10:00 AM ET

Philadelphia, PA United States

Discovery of Novel Oral Peptide Antagonists of IL-23 Receptor that are Efficacious in Rat Model of IBD

Tue, 15 Dec 2015 20:44:50 GMT

PTG-100, an Oral Peptide Antagonist of Integrin α4β7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models

Tue, 15 Dec 2015 20:32:32 GMT

Preclinical Characterization of PTG-100, an Oral α4β7 Integrin Peptide Antagonist for Treatment of Ulcerative Colitis

Mon, 14 Dec 2015 20:34:52 GMT

Discovery and Characterization of Novel Oral Peptide Antagonists of Human IL-23 Receptor that are Efficacious in a Rat Model of IBD

Tue, 01 Dec 2015 20:46:41 GMT

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

Tue, 10 Nov 2015 20:57:19 GMT

Integrin α4β7: Discovery of Gut-Restrictive Oral Peptide Antagonists that are Active in Murine Models of Inflammatory Bowel Disease

Sat, 20 Dec 2014 20:36:52 GMT

Conformational searching using a population-based incremental learning algorithm

Tue, 01 Feb 2011 20:58:36 GMT

Defining scaffold geometries for interacting with proteins: geometrical classification of secondary structure linking regions

Thu, 23 Sep 2010 20:00:23 GMT

Library of biphenyl privileged substructures using a safety-catch linker approach

Thu, 08 May 2008 20:01:44 GMT

Cyclic tetrapeptides via the ring contraction strategy: chemical techniques useful for their identification

Thu, 28 Feb 2008 21:03:22 GMT